Figure 1: Répartition de la population en fonction du niveau d’IMC selon le rapport Obépi 2012
Tableau I: Définitions du syndrome métabolique
Schéma 1 : Actions de l’insuline chez les individus sains Schéma 2 :Physiopathologie des stéatopathies métaboliques Figure 2 : Aspects histopathologiques des NAFLD
Tableau II: Score NAS et fibrose selon Kleiner et al.
Tableau III: Score SAF et algorithme diagnostique selon Bedossa et al.
Tableau IV. Caractéristiques histopathologiques des 857 patients obèses morbides Tableau V. Données cliniques et biologiques des 857 patients obèses morbides répartis selon la présence ou non de NASH
Tableau VI. Données cliniques et biologiques des 857 patients obèses morbides répartis selon la présence ou non de NAFLD et de NASH
Tableau VII. Capacité à diagnostiquer une NAFLD ou une NASH de l’ALAT et des marqueurs de l’insulino-résistance (n=857)
Tableau VIII. Caractéristiques histopathologiques des 362 patients obèses morbides Tableau IX. Données cliniques et biologiques des 362 patients obèses morbides répartis selon la présence ou non de NASH
Tableau X. Données cliniques et biologiques des 362 patients obèses morbides répartis selon la présence ou non de NAFLD et de NASH
Tableau XI. Valeurs diagnostiques (AUROCs) pour la présence de NAFLD et de NASH (n=362)
Figure 3 : Courbes ROC pour le diagnostic de NAFLD et de NASH (n=362)
Figure 4 et 5 : Marqueurs potentiels de NASH: valeurs selon le grade de stéatose et corrélation (n=362)
Tableau XII : Valeurs de l’HOMA-IR, l’ALAT et des marqueurs sériques de mort selon la présence ou non de NASH pour un même grade de stéatose (n=362)
Tableau XIII : Performance de différents modèles pour le diagnostic de NASH (n=362)
Figure 6 : Valeur diagnostique du Modèle 1 pour le diagnostic de NASH : Age, ALAT, adipose-IR, marqueur de mort totale
Figure 7 : Valeur diagnostique du Modèle 2 pour le diagnostic de NASH : Âge, tour de taille, HOMA-IR, marqueur de mort
ϳϬ
BIBLIOGRAPHIE
[1] Paradis, V., Zalinski, S., Chelbi, E., Guedj, N., Degos, F., Vilgrain, V., Bedossa, P., and Belghiti, J., 2009, "Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis," Hepatology, 49(3), pp. 851-859.
[2] Alberti, K. G., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J. C., James, W. P., Loria, C. M., Smith, S. C., Jr., International Diabetes Federation Task Force on, E., Prevention, Hational Heart, L., Blood, I., American Heart, A., World Heart, F., International Atherosclerosis, S., and International Association for the Study of, O., 2009, "Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity," Circulation, 120(16), pp. 1640-1645.
[3] Ford, E. S., 2005, "Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S," Diabetes care, 28(11), pp. 2745-2749.
[4] Balkau, B., Vernay, M., Mhamdi, L., Novak, M., Arondel, D., Vol, S., Tichet, J., Eschwege, E., and Group, D. E. S. I. R. S., 2003, "The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study," Diabetes & metabolism, 29(5), pp. 526-532.
[5] Bedogni, G., Miglioli, L., Masutti, F., Tiribelli, C., Marchesini, G., and Bellentani, S., 2005, "Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study," Hepatology, 42(1), pp. 44-52.
[6] Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., and Marchesini, G., 2010, "A position statement on NAFLD/NASH based on the EASL 2009 special conference," Journal of hepatology, 53(2), pp. 372-384.
[7] Angulo, P., 2002, "Nonalcoholic fatty liver disease," The New England journal of medicine, 346(16), pp. 1221-1231.
[8] Machado, M., Marques-Vidal, P., and Cortez-Pinto, H., 2006, "Hepatic histology in obese patients undergoing bariatric surgery," Journal of hepatology, 45(4), pp. 600- 606.
[9] Mazen, I., El-Gammal, M., Abdel-Hamid, M., and Amr, K., 2009, "A novel homozygous missense mutation of the leptin gene (N103K) in an obese Egyptian patient," Molecular genetics and metabolism, 97(4), pp. 305-308.
[10] Bell, C. G., Meyre, D., Samson, C., Boyle, C., Lecoeur, C., Tauber, M., Jouret, B., Jaquet, D., Levy-Marchal, C., Charles, M. A., Weill, J., Gibson, F., Mein, C. A., Froguel, P., and Walley, A. J., 2005, "Association of melanin-concentrating hormone receptor 1 5' polymorphism with early-onset extreme obesity," Diabetes, 54(10), pp. 3049-3055.
[11] Panchal, S. K., and Brown, L., 2011, "Rodent models for metabolic syndrome research," Journal of biomedicine & biotechnology, 2011, p. 351982.
[12] Clarke, S. F., Murphy, E. F., Nilaweera, K., Ross, P. R., Shanahan, F., O'Toole, P. W., and Cotter, P. D., 2012, "The gut microbiota and its relationship to diet and obesity: new insights," Gut microbes, 3(3), pp. 186-202.
[13] Stein, C. J., and Colditz, G. A., 2004, "The epidemic of obesity," The Journal of clinical endocrinology and metabolism, 89(6), pp. 2522-2525.
[14] Lopez, R. P., and Hynes, H. P., 2006, "Obesity, physical activity, and the urban environment: public health research needs," Environmental health : a global access science source, 5, p. 25.
ϳϭ [15] Cizza, G., and Rother, K. I., 2012, "Beyond fast food and slow motion: weighty contributors to the obesity epidemic," Journal of endocrinological investigation, 35(2), pp. 236-242.
[16] Day, C. P., and James, O. F., 1998, "Steatohepatitis: a tale of two "hits"?," Gastroenterology, 114(4), pp. 842-845.
[17] Dowman, J. K., Tomlinson, J. W., and Newsome, P. N., 2010, "Pathogenesis of non-alcoholic fatty liver disease," QJM : monthly journal of the Association of Physicians, 103(2), pp. 71-83.
[18] Feldstein, A. E., Werneburg, N. W., Canbay, A., Guicciardi, M. E., Bronk, S. F., Rydzewski, R., Burgart, L. J., and Gores, G. J., 2004, "Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway," Hepatology, 40(1), pp. 185-194.
[19] Tilg, H., and Moschen, A. R., 2010, "Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis," Hepatology, 52(5), pp. 1836- 1846.
[20] Alkhouri, N., Carter-Kent, C., and Feldstein, A. E., 2011, "Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications," Expert review of gastroenterology & hepatology, 5(2), pp. 201-212.
[21] Cadranel, J. F., Rufat, P., and Degos, F., 2000, "Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF)," Hepatology, 32(3), pp. 477-481.
[22] Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y. C., Torbenson, M. S., Unalp-Arida, A., Yeh, M., McCullough, A. J., Sanyal, A. J., and Nonalcoholic Steatohepatitis Clinical Research, N., 2005, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease," Hepatology, 41(6), pp. 1313-1321.
[23] Brunt, E. M., 2000, "Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond," Hepatology, 31(1), pp. 241-246.
[24] Bedossa, P., Poitou, C., Veyrie, N., Bouillot, J. L., Basdevant, A., Paradis, V., Tordjman, J., and Clement, K., 2012, "Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients," Hepatology, 56(5), pp. 1751-1759.
[25] Obika, M., and Noguchi, H., 2012, "Diagnosis and evaluation of nonalcoholic fatty liver disease," Experimental diabetes research, 2012, p. 145754.
[26] Chen, J., Talwalkar, J. A., Yin, M., Glaser, K. J., Sanderson, S. O., and Ehman, R. L., 2011, "Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography," Radiology, 259(3), pp. 749-756.
[27] Machado, M. V., and Cortez-Pinto, H., 2013, "Non-invasive diagnosis of non- alcoholic fatty liver disease. A critical appraisal," Journal of hepatology, 58(5), pp. 1007-1019.
[28] Adams, L. A., Sanderson, S., Lindor, K. D., and Angulo, P., 2005, "The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies," Journal of hepatology, 42(1), pp. 132-138. [29] Mofrad, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., Sterling, R. K., Shiffman, M. L., Stravitz, R. T., and Sanyal, A. J., 2003, "Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values," Hepatology, 37(6), pp. 1286-1292.
ϳϮ [30] Sorrentino, P., Tarantino, G., Conca, P., Perrella, A., Terracciano, M. L., Vecchione, R., Gargiulo, G., Gennarelli, N., and Lobello, R., 2004, "Silent non- alcoholic fatty liver disease-a clinical-histological study," Journal of hepatology, 41(5), pp. 751-757.
[31] Feldstein, A. E., Wieckowska, A., Lopez, A. R., Liu, Y. C., Zein, N. N., and McCullough, A. J., 2009, "Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study," Hepatology, 50(4), pp. 1072-1078.
[32] Lavallard, V. J., Bonnafous, S., Patouraux, S., Saint-Paul, M. C., Rousseau, D., Anty, R., Le Marchand-Brustel, Y., Tran, A., and Gual, P., 2011, "Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease," PloS one, 6(3), p. e17599.
[33] Yoneda, M., Mawatari, H., Fujita, K., Iida, H., Yonemitsu, K., Kato, S., Takahashi, H., Kirikoshi, H., Inamori, M., Nozaki, Y., Abe, Y., Kubota, K., Saito, S., Iwasaki, T., Terauchi, Y., Togo, S., Maeyama, S., and Nakajima, A., 2007, "High-sensitivity C- reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH," Journal of gastroenterology, 42(7), pp. 573-582.
[34] Anty, R., Bekri, S., Luciani, N., Saint-Paul, M. C., Dahman, M., Iannelli, A., Amor, I. B., Staccini-Myx, A., Huet, P. M., Gugenheim, J., Sadoul, J. L., Le Marchand- Brustel, Y., Tran, A., and Gual, P., 2006, "The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH," The American journal of gastroenterology, 101(8), pp. 1824-1833.
[35] Hui, J. M., Farrell, G. C., Kench, J. G., and George, J., 2004, "High sensitivity C- reactive protein values do not reliably predict the severity of histological changes in NAFLD," Hepatology, 39(5), pp. 1458-1459.
[36] Zimmermann, E., Anty, R., Tordjman, J., Verrijken, A., Gual, P., Tran, A., Iannelli, A., Gugenheim, J., Bedossa, P., Francque, S., Le Marchand-Brustel, Y., Clement, K., Van Gaal, L., Sorensen, T. I., and Jess, T., 2011, "C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients," Journal of hepatology, 55(3), pp. 660-665.
[37] Anty, R., Iannelli, A., Patouraux, S., Bonnafous, S., Lavallard, V. J., Senni- Buratti, M., Amor, I. B., Staccini-Myx, A., Saint-Paul, M. C., Berthier, F., Huet, P. M., Le Marchand-Brustel, Y., Gugenheim, J., Gual, P., and Tran, A., 2010, "A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients," Alimentary pharmacology & therapeutics, 32(11-12), pp. 1315-1322.
[38] Poynard, T., Ratziu, V., Charlotte, F., Messous, D., Munteanu, M., Imbert- Bismut, F., Massard, J., Bonyhay, L., Tahiri, M., Thabut, D., Cadranel, J. F., Le Bail, B., de Ledinghen, V., Group, L. S., and group, C. s., 2006, "Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease," BMC gastroenterology, 6, p. 34.
[39] Angulo, P., Keach, J. C., Batts, K. P., and Lindor, K. D., 1999, "Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis," Hepatology, 30(6), pp. 1356-1362.
[40] Yoneda, M., Mawatari, H., Fujita, K., Yonemitsu, K., Kato, S., Takahashi, H., Kirikoshi, H., Inamori, M., Nozaki, Y., Abe, Y., Kubota, K., Saito, S., Iwasaki, T., Terauchi, Y., Togo, S., Maeyama, S., and Nakajima, A., 2007, "Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with
ϳϯ nonalcoholic steatohepatitis before the cirrhotic stage," Journal of gastroenterology, 42(5), pp. 375-381.
[41] Veillon, P., Gallois, Y., Moal, V., Fouchard-Hubert, I., Charles, I., Larcher, F., Dib, N., Boursier, J., Oberti, F., Laafi, J., Guechot, J., Balan, V., Cales, P., and Lunel- Fabiani, F., 2011, "Assessment of new hyaluronic acid assays and their impact on FibroMeter scores," Clinica chimica acta; international journal of clinical chemistry, 412(3-4), pp. 347-352.
[42] Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., Lindor, K., Sanderson, S. O., Lenzi, M., Adams, L. A., Kench, J., Therneau, T. M., and Day, C. P., 2007, "The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD," Hepatology, 45(4), pp. 846-854.
[43] Cales, P., Boursier, J., de Ledinghen, V., Halfon, P., Bacq, Y., Leroy, V., Dib, N., Oberti, F., Sawadogo, A., Rousselet, M. C., and Lunel, F., 2008, "Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests," Gastroenterologie clinique et biologique, 32(12), pp. 1050-1060.
[44] Cales, P., Oberti, F., Michalak, S., Hubert-Fouchard, I., Rousselet, M. C., Konate, A., Gallois, Y., Ternisien, C., Chevailler, A., and Lunel, F., 2005, "A novel panel of blood markers to assess the degree of liver fibrosis," Hepatology, 42(6), pp. 1373-1381.
[45] Cales, P., Boursier, J., Oberti, F., Hubert, I., Gallois, Y., Rousselet, M. C., Dib, N., Moal, V., Macchi, L., Chevailler, A., Michalak, S., Hunault, G., Chaigneau, J., Sawadogo, A., and Lunel, F., 2008, "FibroMeters: a family of blood tests for liver fibrosis," Gastroenterologie clinique et biologique, 32(6 Suppl 1), pp. 40-51.
[46] Wong, G. L., 2013, "Transient elastography: Kill two birds with one stone?," World journal of hepatology, 5(5), pp. 264-274.
[47] Wong, V. W., Vergniol, J., Wong, G. L., Foucher, J., Chan, H. L., Le Bail, B., Choi, P. C., Kowo, M., Chan, A. W., Merrouche, W., Sung, J. J., and de Ledinghen, V., 2010, "Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease," Hepatology, 51(2), pp. 454-462.
[48] Bota, S., Herkner, H., Sporea, I., Salzl, P., Sirli, R., Neghina, A. M., and Peck- Radosavljevic, M., 2013, "Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis," Liver international : official journal of the International Association for the Study of the Liver.
[49] Hafeez, S., and Ahmed, M. H., 2013, "Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance?," Journal of obesity, 2013, p. 839275.
[50] Van Wagner, L. B., and Rinella, M. E., 2011, "The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis," Therapeutic advances in gastroenterology, 4(4), pp. 249-263.
[51] Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., Van Natta, M., Clark, J., Brunt, E. M., Kleiner, D. E., Hoofnagle, J. H., Robuck, P. R., and Nash, C. R. N., 2010, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis," The New England journal of medicine, 362(18), pp. 1675-1685.
[52] Ratziu, V., Charlotte, F., Bernhardt, C., Giral, P., Halbron, M., Lenaour, G., Hartmann-Heurtier, A., Bruckert, E., Poynard, T., and Group, L. S., 2010, "Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial," Hepatology, 51(2), pp. 445-453.
ϳϰ [53] Musso, G., Gambino, R., Cassader, M., and Pagano, G., 2010, "A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease," Hepatology, 52(1), pp. 79-104.
[54] Lindor, K. D., Kowdley, K. V., Heathcote, E. J., Harrison, M. E., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., and Colin, P., 2004, "Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial," Hepatology, 39(3), pp. 770-778.
[55] Primeau, V., Coderre, L., Karelis, A. D., Brochu, M., Lavoie, M. E., Messier, V., Sladek, R., and Rabasa-Lhoret, R., 2011, "Characterizing the profile of obese patients who are metabolically healthy," International journal of obesity, 35(7), pp. 971-981.
[56] McLaughlin, T., Lamendola, C., Liu, A., and Abbasi, F., 2011, "Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity," The Journal of clinical endocrinology and metabolism, 96(11), pp. E1756- 1760.
[57] Wildman, R. P., Muntner, P., Reynolds, K., McGinn, A. P., Rajpathak, S., Wylie- Rosett, J., and Sowers, M. R., 2008, "The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004)," Archives of internal medicine, 168(15), pp. 1617-1624.
[58] Patel, P., and Abate, N., 2013, "Body fat distribution and insulin resistance," Nutrients, 5(6), pp. 2019-2027.
[59] Hong, H. C., Lee, J. S., Choi, H. Y., Yang, S. J., Yoo, H. J., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., Choi, D. S., and Choi, K. M., 2013, "Liver enzymes and vitamin D levels in metabolically healthy but obese individuals: Korean National Health and Nutrition Examination Survey," Metabolism: clinical and experimental. [60] Messier, V., Karelis, A. D., Robillard, M. E., Bellefeuille, P., Brochu, M., Lavoie, J. M., and Rabasa-Lhoret, R., 2010, "Metabolically healthy but obese individuals: relationship with hepatic enzymes," Metabolism: clinical and experimental, 59(1), pp. 20-24.
[61] Prati, D., Taioli, E., Zanella, A., Della Torre, E., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., Conte, D., Colombo, M., and Sirchia, G., 2002, "Updated definitions of healthy ranges for serum alanine aminotransferase levels," Annals of internal medicine, 137(1), pp. 1-10.
[62] Kunde, S. S., Lazenby, A. J., Clements, R. H., and Abrams, G. A., 2005, "Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women," Hepatology, 42(3), pp. 650-656.
[63] Lomonaco, R., Ortiz-Lopez, C., Orsak, B., Webb, A., Hardies, J., Darland, C., Finch, J., Gastaldelli, A., Harrison, S., Tio, F., and Cusi, K., 2012, "Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease," Hepatology, 55(5), pp. 1389-1397. [64] Diab, D. L., Yerian, L., Schauer, P., Kashyap, S. R., Lopez, R., Hazen, S. L., and Feldstein, A. E., 2008, "Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients," Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 6(11), pp. 1249-1254.
[65] Tamimi, T. I., Elgouhari, H. M., Alkhouri, N., Yerian, L. M., Berk, M. P., Lopez, R., Schauer, P. R., Zein, N. N., and Feldstein, A. E., 2011, "An apoptosis panel for nonalcoholic steatohepatitis diagnosis," Journal of hepatology, 54(6), pp. 1224-1229. [66] Younossi, Z. M., Jarrar, M., Nugent, C., Randhawa, M., Afendy, M., Stepanova, M., Rafiq, N., Goodman, Z., Chandhoke, V., and Baranova, A., 2008, "A novel
ϳϱ diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH)," Obesity surgery, 18(11), pp. 1430-1437.
[67] Tran, A., and Gual, P., 2013, "Non-alcoholic steatohepatitis in morbidly obese patients," Clinics and research in hepatology and gastroenterology, 37(1), pp. 17-29. [68] Yamaguchi, K., Yang, L., McCall, S., Huang, J., Yu, X. X., Pandey, S. K., Bhanot, S., Monia, B. P., Li, Y. X., and Diehl, A. M., 2007, "Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis," Hepatology, 45(6), pp. 1366-1374. [69] Anstee, Q. M., Daly, A. K., and Day, C. P., 2011, "Genetic modifiers of non- alcoholic fatty liver disease progression," Biochimica et biophysica acta, 1812(11), pp. 1557-1566.
[70] Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., and Hobbs, H. H., 2008, "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease," Nature genetics, 40(12), pp. 1461-1465.
[71] Speliotes, E. K., Yerges-Armstrong, L. M., Wu, J., Hernaez, R., Kim, L. J., Palmer, C. D., Gudnason, V., Eiriksdottir, G., Garcia, M. E., Launer, L. J., Nalls, M. A., Clark, J. M., Mitchell, B. D., Shuldiner, A. R., Butler, J. L., Tomas, M., Hoffmann, U., Hwang, S. J., Massaro, J. M., O'Donnell, C. J., Sahani, D. V., Salomaa, V., Schadt, E. E., Schwartz, S. M., Siscovick, D. S., Nash, C. R. N., Consortium, G., Investigators, M., Voight, B. F., Carr, J. J., Feitosa, M. F., Harris, T. B., Fox, C. S., Smith, A. V., Kao, W. H., Hirschhorn, J. N., Borecki, I. B., and Consortium, G., 2011, "Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits," PLoS genetics, 7(3), p. e1001324.
[72] Rotman, Y., Koh, C., Zmuda, J. M., Kleiner, D. E., Liang, T. J., and Nash, C. R. N., 2010, "The association of genetic variability in patatin-like phospholipase domain- containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease," Hepatology, 52(3), pp. 894-903.
[73] Hoekstra, M., Li, Z., Kruijt, J. K., Van Eck, M., Van Berkel, T. J., and Kuiper, J., 2010, "The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status," Journal of hepatology, 52(2), pp. 244-251.
[74] Dixon, J. B., Bhathal, P. S., and O'Brien, P. E., 2001, "Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese," Gastroenterology, 121(1), pp. 91-100.
[75] Brunt, E. M., Kleiner, D. E., Wilson, L. A., Belt, P., Neuschwander-Tetri, B. A., and Network, N. C. R., 2011, "Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings," Hepatology, 53(3), pp. 810-820.
[76] Lassailly, G., Caiazzo, R., Hollebecque, A., Buob, D., Leteurtre, E., Arnalsteen, L., Louvet, A., Pigeyre, M., Raverdy, V., Verkindt, H., Six, M. F., Eberle, C., Patrice, A., Dharancy, S., Romon, M., Pattou, F., and Mathurin, P., 2011, "Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity," European journal of gastroenterology & hepatology, 23(6), pp. 499-506.